A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis

A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple Sclerosis

Registry ID

EUCTR2010-024000-10

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

BIOGEN IDEC LTD

Start date

2011-10-26

Completion date

2014-07-18

Last update

2026-08-16

Conditions

• Relapsing-Remitting Multiple Sclerosis

Summary

To explore the effects of multiple regimens of natalizumab on disease activity and safety in subjects with relapsing remitting MS.

Locations

• , , Belgium
• , , Germany
• , , Spain
• , , Italy

Related clinical trials

• A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

View on source registry